RxDoctor Payments DataLook up a doctor →

Kathryn Pennington, MD

Gynecologic Oncology · Seattle, WANPI 1336265511

Payments from drug & device makers

$601,255in general payments, 2019–2025

Across 517 payments — averaging $1162.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$305K
  • Springworks Therapeutics, Inc.$139K
  • AstraZeneca$121K
  • Genmab U.S., Inc.$34K
  • Merck$795
  • Intuitive Surgical$757
  • plus $398 from 4 others

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK24$304,651
Springworks Therapeutics, Inc.471$139,244
AstraZeneca9$121,410
Genmab U.S., Inc.1$34,000
Merck1$795
Intuitive Surgical2$757
AbbVie6$251
Seagen Inc.1$99
Pfizer1$29
Daiichi Sankyo Inc.1$19

How this compares

$601,255 in reported general payments places this provider in the 80th percentile of 36 gynecologic oncology providers in Washington.

See all gynecologic oncology providers in Washington

Medicare billing

Part B allowed, 2024
$78,206
Medicare patients
147
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →